OXFORD - Genset S.A., the French integrated genomics company, is gearing itself for the post-genome future. And it is a future that is not necessarily an independent one and will involve changes.

The first of those changes was unveiled last week when Genset announced that board member Andre Pernet, formerly vice president of pharmaceutical products R&D at Abbott Laboratories Inc. (ABT, Abbott Park, Ill.), would be taking over as president and CEO from Pascal Brandys, the former venture capitalist and a co-founder of the company.